INNOVATE Corp AI Stock Analysis
Want to see VATE full AI Analyst Report?
INNOVATE Corp (VATE) AI Stock Analysis
INNOVATE Corp
(NYSE:VATE)
The overall score of 52 reflects a company in the midst of a high-stakes transformation. The most significant positive factor is the recent earnings call, which detailed a successful pivot to profitability and a major debt-reducing asset sale that has fundamentally improved the capital structure. This is counterbalanced by a precarious balance sheet with negative equity and deeply bearish technicals, as the stock price remains in a downtrend below all major moving averages. The company's future hinges on the successful execution of its refocused strategy on life sciences, as its legacy financial weaknesses and poor market momentum continue to pose substantial risks.
INNOVATE Corp (VATE) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $62.34M
- Dividend Yield
- ―
- Average Volume (3M)
- 91.93K
- Price to Earnings (P/E)
- -457.0
- Beta (1Y)
- 2.81
- Revenue Growth
- 51.34%
- EPS Growth
- ―
- Country
- US
- Employees
- 3,663
- Sector
- Industrials
- Sector Strength
- 63
- Industry
- Engineering & Construction
INNOVATE Corp Business Overview & Revenue Model
Company Description
INNOVATE Corp. (VATE), a New York-based entity founded in 1994 and previously known as HC2 Holdings, Inc. until its name change in September 2021, manages a diverse range of subsidiaries operating within the infrastructure, life sciences, and spectru...
How the Company Makes Money
INNOVATE Corp makes money primarily through revenue generated by its operating subsidiaries, which sell their products and services to customers in their respective end markets. Cash flow is then used to fund operations at the subsidiary level and su...
INNOVATE Corp Earnings Call Summary
The call was predominantly positive, supported by 42.8% consolidated revenue growth, a return to net income, sharply higher adjusted EBITDA, strong DBMG operating results, completion of the DBMG sale, significant post-quarter debt reduction, and continued commercial and development progress at MediBeacon and R2. The company also reported lower Life Sciences revenue, weaker Spectrum results following the ownership disposition, industrial maintenance margin pressure, and higher indebtedness as of quarter end. Overall, the highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management said initial Transdermal GFR use by big pharma in clinical trials is now anticipated in 2027; MediBeacon has secured orders for 600 TGFR Monitors, with shipments planned from the fourth quarter of 2026 through the second quarter of 2027, although conversion timing for new technology can take six to 12 months. R2 exited the quarter with 116 systems carrying into the fourth quarter, representing roughly $1.9 million of future revenue, with approximately 60 systems currently in production and delivery anticipated by November 30th. Following the DBMG sale, INNOVATE’s total principal indebtedness is now $238.3 million, which it expects to further reduce as it monetizes assets.
INNOVATE Corp Financial Statement Overview
Summary
The financial performance is a tale of two pictures. The income statement and cash flow show a strong operational turnaround with TTM profitability and robust free cash flow. However, the balance sheet is critically weak, with deeply negative equity of -$228.3 million, posing a major solvency risk. This fragile foundation severely drags down the overall financial health score.
Income Statement
58NeutralBalance Sheet
18Very NegativeCash Flow
62Positive| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.66B | 1.25B | 1.11B | 1.42B | 1.64B | 1.21B |
| Gross Profit | 260.20M | 182.20M | 208.80M | 216.00M | 221.40M | 183.70M |
| EBITDA | 165.00M | 57.90M | 74.00M | 63.10M | 62.80M | 31.80M |
| Net Income | 13.00M | -60.60M | -34.60M | -35.20M | -35.90M | -227.50M |
Balance Sheet | ||||||
| Total Assets | 1.02B | 950.10M | 891.10M | 1.04B | 1.15B | 1.08B |
| Cash, Cash Equivalents and Short-Term Investments | 91.50M | 112.10M | 48.80M | 80.80M | 80.40M | 45.50M |
| Total Debt | 641.70M | 717.50M | 719.20M | 771.90M | 785.30M | 684.80M |
| Total Liabilities | 1.22B | 1.17B | 1.05B | 1.20B | 1.18B | 1.09B |
| Stockholders Equity | -228.30M | -230.80M | -180.40M | -165.50M | -103.70M | -84.30M |
Cash Flow | ||||||
| Free Cash Flow | 100.90M | 120.50M | -9.90M | 8.10M | -30.20M | 65.40M |
| Operating Cash Flow | 157.00M | 146.60M | 9.10M | 26.50M | -9.50M | 89.50M |
| Investing Cash Flow | -58.20M | -22.60M | -13.90M | 23.20M | -22.50M | -299.20M |
| Financing Cash Flow | -42.70M | -61.20M | -26.50M | -49.40M | 68.10M | 17.80M |
INNOVATE Corp Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VATE, the sentiment is Negative. The current price of 4.57 is below the 20-day moving average (MA) of 5.48, below the 50-day MA of 6.55, and below the 200-day MA of 8.92, indicating a bearish trend. The MACD of -0.48 indicates Positive momentum. The RSI at 30.33 is Neutral, neither overbought nor oversold. The STOCH value of 16.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VATE.
INNOVATE Corp Risk Analysis
INNOVATE Corp disclosed 87 risk factors in its most recent earnings report. INNOVATE Corp reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksINNOVATE Corp Peers Comparison
Overall Rating
ESOA65Neutral
SHIM54Neutral- VATE52Neutral
SUNE46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ESOA | 65Neutral | $162.71M | 14.48 | 14.64% | 1.61% | 21.21% | 252.85% |
| Sector * | 63Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
| SHIM | 54Neutral | $138.98M | -10.37 | 21.55% | ― | -13.13% | 82.57% |
| VATE | 52Neutral | $63.32M | -457.00 | -5.59% | ― | 51.34% | ― |
| SUNE | 46Neutral | $12.73M | -1.81 | -24.03% | ― | 10.34% | 99.97% |
* Industrials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VATE | INNOVATE Corp | 4.57 | -0.20 | -4.19% | |
| SUNE | Sunation Energy, Inc. | 1.96 | 0.70 | 55.16% | |
| ESOA | Energy Services Of America | 8.72 | -0.97 | -10.06% | |
| SHIM | Shimmick Corporation | 3.25 | 1.10 | 51.16% |
INNOVATE Corp Corporate Events
INNOVATE Reports Strong Third-Quarter Revenue and Earnings Growth
PositiveOn November 12, 2026, INNOVATE reported third-quarter revenue of $495.5 million, net income attributable to common and participating preferred stockholders of $15.8 million, and total adjusted EBITDA of $40.5 million, compared with revenue of $347.1...
INNOVATE Corp amends 2027 convertible notes redemption terms
PositiveINNOVATE Corp. has entered into a supplemental indenture amending the terms of its 9.500% Convertible Senior Secured Notes due 2027, in connection with the stock consideration it received from the sale of DBMG Global Inc. The amendment requires that...
INNOVATE Corp Sells DBM Global, Accelerates Debt Reduction
PositiveOn October 5, 2026, INNOVATE Corp. completed the sale of its majority-owned subsidiary DBM Global, Inc. to IES Holdings, Inc., transferring 100% of DBMG’s shares, including approximately 91.21% previously held through DBM Global Intermediate Holdco a...
INNOVATE Corp completes HC2 stake sale and recapitalization
PositiveOn August 28, 2026, INNOVATE Corp. executed a tenth amendment to its credit agreement with MSD PCOF Partners IX, LLC, extending the maturity of its existing facility to December 31, 2026, reinforcing near-term financing flexibility. On September 1, 2...
MediBeacon’s Kidney Diagnostic Platform Nominated for Prix Galien
PositiveMediBeacon’s TGFR System, which uses the Lumitrace (relmapirazin) fluorescent tracer, a monitor and reusable sensor to deliver point-of-care transdermal kidney function measurements, has been nominated by The Galien Foundation for the 2026 Prix Galie...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026